SCHEMBL30799798

SCHEMBL30799798

NC(=O)C[C@H](N)C(=O)N[C@@H](CC1CCCCC1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.49
GRN P28799 1/20 0.48
SORT1 Q99523 1/20 0.48
CPB2 Q96IY4 11/20 0.46
MMP1 P03956 2/20 0.44
MMP2 P08253 2/20 0.44
MMP3 P08254 2/20 0.44
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
PGGT1B P53609 1/20 0.43
MME P08473 1/20 0.43
ACE P12821 1/20 0.43
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9146938 0.90 LTA4H (0.50) LTA4HGRNSORT1CPB2MMP1
SCHEMBL9146946 0.90 LTA4H (0.50) LTA4HGRNSORT1CPB2MMP1
SCHEMBL29387045 0.88 GRN (0.52) LTA4HGRNSORT1CPB2FNTA
SCHEMBL30799634 0.86 CPB2 (0.46) LTA4HGRNSORT1CPB2MMP1
SCHEMBL30541625 0.85 CPB2 (0.51) LTA4HGRNSORT1CPB2FNTA
SCHEMBL30732913 0.85 CPB2 (0.51) LTA4HGRNSORT1CPB2FNTA
SCHEMBL30799462 0.85 GRN (0.50) LTA4HGRNSORT1CPB2FNTA
SCHEMBL30799559 0.82 CPB2 (0.48) LTA4HGRNSORT1CPB2FNTA
SCHEMBL7205806 0.82 MMP1 (0.58) LTA4HGRNSORT1CPB2MMP1
SCHEMBL7751628 0.82 CPB2 (0.51) LTA4HGRNSORT1CPB2FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 WO disclosed
US-20240360179-A1 STAPLED PEPTIDES AND METHODS THEREOF PARABILIS MEDICINES, INC. 2024-10-31 US disclosed
US-20240116985-A1 STAPLED PEPTIDES AND METHODS THEREOF PARABILIS MEDICINES, INC. 2024-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116985-A1 STAPLED PEPTIDES AND METHODS THEREOF CTNNB1, APC, CTNNA1 LTA4H 4132/4885GRN 537/4885SORT1 1084/4885
US-20240360179-A1 STAPLED PEPTIDES AND METHODS THEREOF CTNNB1, APC, CTNNA1 LTA4H 3933/4885GRN 692/4885SORT1 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.